About the VHIR
Here at the Vall d'Hebron Research Institute (VHIR) we promote biomedical research, innovation and teaching. Over 1,800 people are seeking to understand diseases today so the treatment can be improved tomorrow.
Research
We are working to understand diseases, to find out how they operate and to create better treatments for patients. Get to know about our groups and their lines of research.
People
People are the centre of the Vall d'Hebron Research Institute (VHIR). This is why we are bound by the principles of freedom of research, gender equality and professional attitudes that HRS4R promotes.
Clinical trials
Our work is not just basic or translational; we are leaders in clinical research. Enter and find about the clinical trials we are conducting and why we are a world reference in this field.
Progress
Our aim is to make the research carried out at the Vall d’Hebron Research Institute (VHIR) a driving force for transformation. How? By identifying new channels and solutions for the promotion of people's health and well-being.
Core facilities
We offer specialist support for researchers, internal and external alike, ranging from specific services to preparing complete projects. All this, from a perspective of quality and speed of response.
News
We offer you a gateway for staying up to date on everything going on at the Vall d’Hebron Research Institute (VHIR), from the latest news to future solidarity activities and initiatives that we are organising.
Cardiovascular Diseases group is a translational research group within the Cardiology Department of Vall d’Hebron Hospital that performs laboratory, clinical and epidemiological research. In the CIBERCV network we are within the topic of descriptor 2 “Arterial disease, thrombosis and myocardial ischemia-reperfusion injury”. Our contributions in these topics address the following lines:
In the CIBERESP network, our group is interested in the study of effectiveness/cost-effectiveness of cardiovascular interventions, health outcome research and methods in clinical research. The group has 19 principal investigators, 32 active projects and clinical trial and has been done 142 publications in 2020.
Molecular and cellular biology
Imaging and genetics and personalized medicine and clinical epidemiology
Evolution of technologies and outcomes research
IP: -
Epidemiology, evaluation of new treatments, outcome research
IP: Blanca Gordon Ramírez Collaborators: - Funding agency: Instituto de Salud Carlos III Funding: 6968.39 Reference: PI22/00707 Duration: 01/01/2023 - 30/06/2027
IP: Andrea Guala Collaborators: Ignacio Ferreira González, Pere López Gutierrez, Pere López Gutierrez, Jose Fernando Rodríguez Palomares, Eduardo Ródenas Alesina, Juan Garrido Oliver, Alicia Fresno González, Toni Soriano Colomé, Lydia Dux-Santoy Hurtado, Juan Pablo Betancur Rengifo Funding agency: EUROPEAN COMMISSION Funding: 462500 Reference: DVPS Duration: 01/07/2025 - 30/06/2029
IP: Jorge Pagola Pérez Blanca Collaborators: José Alvarez Sabin, Noelia Rodríguez Villatoro, Jaume Francisco Pascual, Hug Cuellar Calabria, Claudia Meza Burgos, Federica Rizzo Funding agency: Instituto de Salud Carlos III Funding: 61250 Reference: PI24/00333 Duration: 01/01/2025 - 31/12/2027
IP: Antonio Rodríguez Sinovas Collaborators: Laia Yañez Bisbe, Elisabet Miro Casas, Marisol Ruiz Meana, Laura Rubio Unguetti, Gino Freddy Sena Ganse Funding agency: Fundación Eugenio Rodríguez Pascual Funding: 25000 Reference: FERP/2024/RODRIGUEZ Duration: 15/01/2025 - 14/01/2027
PhD student: Ferran Gran Ipiña, Ferran Gran Ipiña, Ferran Gran Ipiña, Ferran Gran Ipiña Director/s: Ferran Rosés i Noguer, Dimpna Calila Albert Brotons, Dimpna Calila Albert Brotons University: Universidad Autònoma de Barcelona Year: 2019
PhD student: Emma Forcadell Drago Director/s: Ignacio Ferreira González University: Universidad Autònoma de Barcelona Year: 2019
PhD student: Laura Valls de Lacalle Director/s: Antonio Rodríguez Sinovas University: Universidad Autònoma de Barcelona Year: 2019
The project’s 4th annual meeting was recently held as part of the Fortalece–Salud programme of the Carlos III Health Institute.
Women have a mortality rate of 21% during the 30 days following surgery, compared with 11% in men, a difference that remains after taking patients’ clinical characteristics into account.
The families of the professionals had the opportunity to visit the facilities and discover how we work at the institution.
Echocardiography Rates
PDF 0.66 MB
Hemodynamics Rates
PDF 0.47 MB
